Terazosin therapy for patients with female lower urinary tract symptoms: A randomized, double-blind, placebo controlled trial
Terazosin therapy for patients with female lower urinary tract symptoms: A randomized, double-blind, placebo controlled trial
复制标题
DOI：
10.1016/j.juro.2007.11.060
复制
发表时间：
2008-04-01
影响因子：
6.6
通讯作者：
Liong, Ker Keong
中科院分区：
文献类型：
--
作者：
Low, Bee Yean;Liong, Men Long;Liong, Ker Keong
目的：我们确定了特拉唑嗪在治疗女性下尿路symptoms. Materials和方法的临床疗效和安全性：共100名女性20至70岁谁符合纳入标准的总国际前列腺症状评分8或更大，症状持续时间I个月或更多，并不符合任何排除标准进入研究。受试者随机接受特拉唑嗪或安慰剂，剂量从1 mg od，1 mg每日两次至2 mg每日两次，持续14周。成功治疗的主要终点为国际前列腺症状评分生活质量≤ 2分，次要终点为国际前列腺症状总评分≤ 7分，其他结局指标包括国际前列腺症状评分单项评分、King's健康问卷生活质量领域、24小时频数容积表客观评估参数、结果：使用主要终点，40名可评价的特拉唑嗪受试者中有32名（80%）有反应，而40名可评价的安慰剂受试者中有22名（55%）有反应（p
Purpose: We determined the clinical efficacy and safety of terazosin in the treatment of patients with female lower urinary tract symptoms.Materials and Methods: A total of 100 females 20 to 70 years old who met the inclusion criteria of total International Prostate Symptom Score 8 or greater, symptom duration I or more months, and did not meet any exclusion criteria were entered into the study. Subjects were randomized to receive terazosin or placebo in titrated dose from 1 mg od, 1 mg twice daily to 2 mg twice daily during 14 weeks. Successful treatment outcomes use primary end point of International Prostate Symptom Score quality of life 2 or less and secondary end point of total International Prostate Symptom Score 7 or less. Other outcome measures included International Prostate Symptom Score individual item scores, King's Health Questionnaire quality of life domains, objective assessment parameters of 24-hour frequency volume chart, maximum flow rate and post-void residual urine.Results: Using a primary end point, 32 of 40 (80%) evaluable terazosin subjects responded in contrast to 22 of 40 (55%) evaluable placebo subjects (p